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Background
Enhanced cGMP-PKG signaling by PDE5 inhibitor (silde-
nafil) ameliorates cardiac mal-adaptive hypertrophy/
remodeling. Although Gq inhibition via PKG-RGS2 acti-
vation is an essential mechanism for the early stage anti-
hypertrophy under pressure-overload (TAC) in mice, the
mechanism for the advanced disease stage remains
unknown.
Results
Impaired mitochondrial respiration was observed in
advanced stage dilative 9wk TAC hearts, associated with
down-regulation of PGC1a, but not in 1-3 wk TAC hearts.
Delayed sildenafil treatment (100mg/kg/day) initiated after
hypertrophy establishment (1-3 wk TAC) inhibited pro-
gression of remodeling up to 9wks, which was associated
with restored PGC1a expression and preserved mitochon-
drial function, but not with RGS2 activation. Mice lacking
RGS2 develop exacerbated early hypertrophy (1wk TAC)
which is unresponsive to sildenafil, whereas sildenafil
treatment initiated after 1wk ameliorated long term (up to
7wk) progression of cardiac remodeling and function, with
restored PGC1a expression and improved mitochondrial
respiratory function. Importantly, similar findings were
obtained in PKG1a leucine zipper knock-in animals,
wherein RGS2-PKG interaction is disrupted. In rat neona-
tal cardiac myocytes (RNCM), 72hr exposure to pheny-
lephrine (Gq agonist, 20µM) down-regulated PGC1a and
impaired mitochondrial respiration, both of which were
normalized by sildenafil co-treatment (1µM). Over-expres-
sion of PKG up-regulated PGC1a in RNCM, increasing
mitochondrial respiration, whereas this was not observed
when PGC1a was silenced.
Conclusion
These results suggest enhancing cGMP-PKG signaling
by sildenafil improves cardiac energetics by restoring
myocyte PGC1a and thereby ameliorates remodeling
progression in advanced stage of pressure-overload
hypertrophy, independently of RGS2.
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